Search research articles
Contact Us
Filters
Showing results (181-190 of 189) with videos related to
Page
of 19
Sort By:
You have reached the last page of results.
This site can display upto 189 results.
European Journal of Cancer (Oxford, England : 1990)
|
December 31, 2002
Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report
M Marchand, C J A Punt, S Aamdal, et al.
Clinical Genetics
|
March 17, 2017
Reassessing the clinical spectrum associated with hereditary leiomyomatosis and renal cell carcinoma syndrome in French FH mutation carriers
M Muller, S Ferlicot, M Guillaud-Bataille, et al.
ESMO Open
|
April 20, 2024
Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial
T Powles, M Burotto, B Escudier, et al.
ESMO Open
|
June 19, 2024
Nivolumab in patients with advanced renal cell carcinoma in France: interim results of the observational, real-world WITNESS study
P Barthélémy, L Albigès, B Escudier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 25, 2025
Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial
R J Motzer, B Escudier, M Burotto, et al.
ESMO Open
|
December 6, 2024
Nivolumab plus relatlimab and nivolumab plus ipilimumab for patients with advanced renal cell carcinoma: results from the open-label, randomised, phase II FRACTION-RCC trial
T K Choueiri, T M Kuzel, S S Tykodi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 5, 2026
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial
T K Choueiri, L Albigès, D F McDermott, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 1, 2016
International cancer seminars: a focus on kidney cancer
G Scelo, J N Hofmann, R E Banks, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 16, 2015
Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project†
A Kramar, S Negrier, R Sylvester, et al.
Page
of 19
Search research articles
Search
Showing results (181-190 of 189) with videos related to
Sort By:
Page
of 19
You have reached the last page of results.
This site can display upto 189 results.
European Journal of Cancer (Oxford, England : 1990)
|
December 31, 2002
Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report
M Marchand, C J A Punt, S Aamdal, et al.
Clinical Genetics
|
March 17, 2017
Reassessing the clinical spectrum associated with hereditary leiomyomatosis and renal cell carcinoma syndrome in French FH mutation carriers
M Muller, S Ferlicot, M Guillaud-Bataille, et al.
ESMO Open
|
April 20, 2024
Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial
T Powles, M Burotto, B Escudier, et al.
ESMO Open
|
June 19, 2024
Nivolumab in patients with advanced renal cell carcinoma in France: interim results of the observational, real-world WITNESS study
P Barthélémy, L Albigès, B Escudier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 25, 2025
Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial
R J Motzer, B Escudier, M Burotto, et al.
ESMO Open
|
December 6, 2024
Nivolumab plus relatlimab and nivolumab plus ipilimumab for patients with advanced renal cell carcinoma: results from the open-label, randomised, phase II FRACTION-RCC trial
T K Choueiri, T M Kuzel, S S Tykodi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 5, 2026
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial
T K Choueiri, L Albigès, D F McDermott, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 1, 2016
International cancer seminars: a focus on kidney cancer
G Scelo, J N Hofmann, R E Banks, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 16, 2015
Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project†
A Kramar, S Negrier, R Sylvester, et al.
Page
of 19